New Autism Research to be Presented at European Purine Scientific Meeting
Rhea-AI Summary
Marvel Biosciences (OTC:MBCOF) announced that collaborator Dr. Jérôme Becker from the iBraiN Institute will present at the 3rd European Purine Meeting in Bordeaux, France, from July 1–3, 2026.
The talk will cover adenosine A2A receptors in autism and preclinical work on Marvel’s lead A2A antagonist MB-204, developed over a three-year collaboration, and highlight Marvel’s progress toward Phase 1 clinical studies.
Positive
- None.
Negative
- None.
News Market Reaction – MBCOF
In the Jun 26 session, MBCOF gained 2.84%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CALGARY, Alberta, June 26, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce one of their collaborators from the iBraiN Institute in Tours France, Dr. Jérôme Becker, will give an oral presentation at the 3rd European Purine Meeting, taking place in Bordeaux, France, from July 1 to 3, 2026. Marvel is also proud to support the meeting as a conference gold sponsor.
Dr. Becker’s presentation, “Adenosine A2A Receptors as a Therapeutic Target in Autism Spectrum Disorders”, will be given next Friday. The presentation will highlight the pivotal role that Adenosine A2a receptors (A2ARs) play in the neural reward circuits involved in social interaction and communication. Research shows that A2AR antagonism consistently improves social interaction across multiple preclinical models displaying autism-like phenotypes, suggesting that drugs that target the A2AR are a very promising therapeutic target to alleviate social deficits associated with autism spectrum disorders.
Marvel and Dr. Becker and Dr. Julie Le Merrer’s research team at the iBraiN institute have collaborated for the past three years to advance the scientific understanding of A2AR biology and evaluate the therapeutic potential of MB-204, Marvel's lead A2AR antagonist, in multiple preclinical models of autism (e.g., Oprm1, Mecp2, Shank3 – data forthcoming).
"Dr. Becker is a world-class researcher whose work has been instrumental in advancing the understanding of adenosine A2A receptors in autism," said Rod Matheson, Chief Executive Officer of Marvel Biosciences. "Over the past three years, our collaboration has generated compelling preclinical data demonstrating the potential of MB-204 across multiple validated models of autism. Marvel Biosciences is proud to support the European Purine Meeting, and we hope this will raise greater awareness of this field of research in autism. "
The Company is also pleased to share its recent interview with Radius Research, featuring Chief Executive Officer, Rod Matheson, and Chief Science Officer, Mark Williams. The interview shares insight into Marvel's patented lead asset, MB-204, the Company's development roadmap, upcoming milestones, and the opportunities ahead as Marvel advances toward Phase 1 clinical studies.
Link to interview: https://www.youtube.com/watch?v=dR_XMSsRrdQ
About Marvel Biosciences Corp.
Marvel Biosciences Corp., through its wholly owned subsidiary Marvel Biotechnology Inc., is a Calgary-based biotechnology company developing new treatments for neurological diseases and neurodevelopmental disorders. Our lead drug candidate, MB-204, is a novel fluorinated derivative version of Istradefylline, an approved Parkinson’s drug and the only adenosine A2A receptor blocker currently on the market.
Research shows that blocking the A2A receptor may help treat conditions such as autism, depression, and Alzheimer’s disease. Marvel is also exploring MB-204’s potential in rare disorders like Rett syndrome and Fragile X syndrome, aiming to bring new options to patients with few effective treatments.
Contact Information: Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer
Email: rod@marvelbiosciences.com
Dr. Mark Williams, President and Chief Science Officer
Email: mark@marvelbiosciences.com
Tel: 403 770 2469
Website: www.marvelbiotechnology.com | Twitter/X | LinkedIn
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party.
This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.
